Maury Raycroft
Stock Analyst at Jefferies
(1.43)
# 3,474
Out of 5,067 analysts
54
Total ratings
34.15%
Success rate
-8.68%
Average return
Main Sectors:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AUPH Aurinia Pharmaceuticals | Upgrades: Buy | $10 → $21 | $16.11 | +30.35% | 1 | Nov 7, 2025 | |
| OPK OPKO Health | Downgrades: Hold | $2 → $1.6 | $1.30 | +23.08% | 1 | Oct 31, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $550 → $549 | $434.23 | +26.43% | 4 | Oct 30, 2025 | |
| KZR Kezar Life Sciences | Downgrades: Hold | $18 → $7 | $6.24 | +12.18% | 2 | Oct 17, 2025 | |
| KOD Kodiak Sciences | Initiates: Buy | $15 | $21.87 | -31.41% | 1 | Sep 22, 2025 | |
| CRDF Cardiff Oncology | Initiates: Hold | $3.5 | $2.08 | +68.27% | 1 | Jun 24, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $11.44 | +363.29% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $4.95 | +61.62% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.42 | +620.12% | 1 | Dec 31, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $1.79 | +291.06% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.89 | +107.61% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $10.33 | +83.93% | 1 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $23 → $15 | $3.79 | +295.78% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $39 | $43.68 | -10.71% | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.59 | +916.60% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.59 | +1,346.54% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $4.17 | +4,576.26% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $6.83 | +61.05% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $29.24 | -79.48% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $44.26 | +69.45% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $9.77 | +12.59% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $22.26 | +21.29% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.85 | +170.26% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $101.15 | -52.55% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $8.88 | +305.41% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $4.91 | +2,038.49% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $51.25 | +235.61% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $3.85 | +1,120.78% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $8.35 | +402.99% | 3 | Nov 1, 2017 |
Aurinia Pharmaceuticals
Nov 7, 2025
Upgrades: Buy
Price Target: $10 → $21
Current: $16.11
Upside: +30.35%
OPKO Health
Oct 31, 2025
Downgrades: Hold
Price Target: $2 → $1.6
Current: $1.30
Upside: +23.08%
Alnylam Pharmaceuticals
Oct 30, 2025
Maintains: Buy
Price Target: $550 → $549
Current: $434.23
Upside: +26.43%
Kezar Life Sciences
Oct 17, 2025
Downgrades: Hold
Price Target: $18 → $7
Current: $6.24
Upside: +12.18%
Kodiak Sciences
Sep 22, 2025
Initiates: Buy
Price Target: $15
Current: $21.87
Upside: -31.41%
Cardiff Oncology
Jun 24, 2025
Initiates: Hold
Price Target: $3.5
Current: $2.08
Upside: +68.27%
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $11.44
Upside: +363.29%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $4.95
Upside: +61.62%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.42
Upside: +620.12%
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $1.79
Upside: +291.06%
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $2.89
Upside: +107.61%
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $10.33
Upside: +83.93%
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $3.79
Upside: +295.78%
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $43.68
Upside: -10.71%
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.59
Upside: +916.60%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.59
Upside: +1,346.54%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $4.17
Upside: +4,576.26%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $6.83
Upside: +61.05%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $29.24
Upside: -79.48%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $44.26
Upside: +69.45%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $9.77
Upside: +12.59%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $22.26
Upside: +21.29%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.85
Upside: +170.26%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $101.15
Upside: -52.55%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $8.88
Upside: +305.41%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $4.91
Upside: +2,038.49%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $51.25
Upside: +235.61%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $3.85
Upside: +1,120.78%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $8.35
Upside: +402.99%